AVIEW vs ElucidVivo A.3
AI Verdict
Choose AVIEW if…
Choose AVIEW if your primary need is a comprehensive AI platform for the early detection, diagnosis, and monitoring of various lung pathologies, including lung cancer, COPD, and Interstitial Lung Disease (ILD), alongside initial cardiovascular risk assessment through coronary artery calcification (CAC) scoring. This tool is ideal for radiologists and pulmonologists seeking to streamline workflows for general thoracic health screening and follow-up, offering detailed nodule analysis, emphysema quantification, and automated segmentation.
View AVIEW →Choose ElucidVivo A.3 if…
Choose ElucidVivo A.3 if your focus is on advanced, quantitative analysis of arterial plaque composition and stability from CT angiography to stratify atherosclerosis patients and optimize treatment decisions. This system is particularly well-suited for cardiologists and vascular surgeons requiring precise, histology-validated measurements of plaque components like Lipid-Rich Necrotic Core (LRNC), matrix, and calcifications, and for deriving functional insights such as fractional flow reserve (FFRct).
View ElucidVivo A.3 →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | AVIEW | ElucidVivo A.3 |
|---|---|---|
| Pricing | Subscription; one-off payment | Unknown |
| Deployment | Cloud-based; Hybrid solution; Locally on dedicated hardware; Locally virtualized (virtual machine, Docker) | Cloud and on-premise secure deployment. |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
AVIEWAVIEW offers comprehensive workflow automation, integration with PACS/RIS/CIS, and flexible deployment options including cloud, hybrid, local, and virtualized solutions. Its accessibility via mobile devices and Chrome browsers, along with automated report generation, suggests a more streamlined and user-friendly experience.
Clinical Value
ElucidVivo A.3ElucidVivo A.3 provides exceptionally strong clinical value through its highly specialized and histologically validated quantitative analysis of arterial plaque composition and stability, including the derivation of fractional flow reserve (FFRct). This depth of insight and demonstrated 40% improvement in predictive accuracy for adverse events offers a profound impact on patient stratification and treatment optimization for atherosclerosis.
Pricing & Value
AVIEWAVIEW offers transparent pricing information, detailing both one-off payment and subscription models based on installations and users. This upfront clarity allows potential customers to better assess the cost and value proposition compared to ElucidVivo A.3, which requires direct contact for pricing.
Enterprise Readiness
ElucidVivo A.3ElucidVivo A.3 explicitly details DICOM integration, PACS/EMR interoperability, and states 'SOC 2 / HIPAA-aligned data protection,' demonstrating a robust commitment to enterprise IT and security standards. While AVIEW offers flexible deployment, its stated limitation to GE CT equipment for AVIEW CAC could hinder broader enterprise adoption.
Innovation
ElucidVivo A.3ElucidVivo A.3 demonstrates superior innovation through its unique, histologically validated quantitative analysis of arterial plaque composition and stability, including the derivation of fractional flow reserve (FFRct). Being the first and only FDA-cleared tool to quantify morphology from CTA as if performed ex vivo by a pathologist, and having a new CPT code, underscores its groundbreaking advancements in cardiovascular diagnostics.
Support & Docs
AVIEWWhile neither tool provides comprehensive details on customer support channels, AVIEW's information explicitly references user manuals and provides access to various technical documentation and catalogs. This suggests a more accessible and structured approach to user documentation compared to ElucidVivo A.3, for which specific user-facing support or documentation was not readily found.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | AVIEW | ElucidVivo A.3 |
|---|---|---|
| Name | AVIEW | ElucidVivo A.3 |
| Company | Coreline Soft Co. | Elucid Bioimaging |
| Primary Diagnostic Focus | Early detection, diagnosis, and monitoring of lung cancer, COPD, and coronary artery calcification from CT scans. | Quantitative analysis of arterial plaque composition and stability from CT angiography for atherosclerosis patient stratification. |
| Key AI Analysis Capabilities | AI-powered lung nodule detection and characterization, emphysema quantification, coronary artery calcium (CAC) scoring, automated segmentation of lung lobes/airways/vessels/coronary arteries, ILD pattern analysis. | AI-powered quantitative analysis of arterial plaque (Lipid-Rich Necrotic Core (LRNC), matrix, and calcifications), derives fractional flow reserve (FFRct). |
| Specialties | Cardiology, Pulmonology, Radiology | Cardiology, Radiology, Vascular Surgery |
Videos
Demos, reviews, and walkthroughs featuring AVIEW and ElucidVivo A.3.